Dr. Dietmar Reichert

Facharzt für Innere Medizin, Hämatologie und Internistische Onkologie, Palliativmedizin, Flugmedizin

  • 1983 Staatsexamen Universität Rostock 
  • 1986 Promotion Universität Rostock  

Ausbildung "Innere Medizin"

  • Klinikum der Hansestadt Stralsund 
  • 1988 FA Innere Medizin

Ausbildung "Hämatologie / Onkologie / Palliativmedizin"

  • Klinikum Oldenburg, Medizinische Klinik II (Direktor: Prof. H.-J. Illiger, Prof. C.-H. Köhne) 
  • 1997 FA Innere Medizin – Hämatologie und Internistische Onkologie 
  • 2005 ESMO Examen 
  • 2006 Palliativmedizin
  • 2016 Fachgebundene genetische Beratung - Innere Medizin

Mitgliedschaften

  • CESAR Central European Society for Anticancer Drug Research 
  • DGHO Deutsche Gesellschaft für Hämatologie und Onkologie 
  • AGIHO Arbeitsgemeinschaft Infektionen in der Hämatologie und Onkologie
  • Deutsche Krebsgesellschaft 
  • AIO Arbeitsgemeinschaft Internistische Onkologie 
  • AGO Arbeitsgemeinschaft Gynäkologische Onkologie 
  • BNHO Bundesverband der niedergelassenen Hämatologen und Onkologen 
  • NiO Niedergelassene Internistische Onkologen Niedersachsen e.V. 
  • DFV Deutscher Fliegerarztverband

Publikationen

  1. Retrograde Studie über die Wertigkeit von Prognosefaktoren bei Gestationsbedingten Trophoblasttumoren (Inaugural-Dissertation) Universität Rostock, 1986
  2. Early Infectious Complications after High-Dose Therapy and Autologous Blood Stem Cell Transplantation. B Metzner, R Dirks, W Gebauer, D Reschke, TH Müller, E Ost, D Reichert, B Rosien, F del Valle, I Zirpel, J Hellkamp, KP Kohse, F Schunter, HJ Illier, DGHO 1998
  3. Pharmacakinetics and Toxicity of PEG-Asparaginase in combination with high-dose methotrexate (HD-MTX). O Rosen, W Langer, N Gökbuget, R Mück, N Peter, D Reichert, F Rothmann, S Schwartz, R Arnold, HJ Müller, J Boos, D Hoelzer, DGHO 1999
  4. A Surveillance Study to Evaluate the Clinical Safety and Therapeutic Efficacy of a Combination Therapy with Flucytosine (Ancotil®) in the Treatment of Patients with Deep Seated Mycosis. Congress of the European Confederation of Medical Mycology, Barcelona 2000
  5. CESAR-EWIV: A Platform for developing new Anticancer Anticancer Agents. C Dittrich, D Arndt, J Beck, D Behringer, C Bokemeyer, W Berdel, M Borner, M DeSantis, L Edler, G Eisenbrandt, I Fichtner, HH Fiebig, G Fricker, G Gastl, G Hartung, R Hofheinz, D Hossfeld, HJ Illiger, U Jaehde, B Keppler, R Morant, K Mross, H Müller, C Oberhoff, W Queißer, D Reichert, R Reszka, M Scheulen, J Schüller, D Strumberg, J von Pawel, M Wessler J Cancer Res Clin Oncol 128 (2002) Supp.1
  6. Late infectious complications after high dose therapy (HDT) and autologous stem cell transplantation (ASCT) B Metzner, R Grüneisl, W Gebauer, D Reschke, E Ost, R Husmann, M Klee, D Reichert, B Rosien, F del Valle, I Zirpel, KP Kohse, F Schunter, HJ Illiger DGHO 2002
  7. Späte infektiöse Komplikationen nach Hochdosistherapie und autologer Blutstammzelltransplantation. B Metzner, R Grüneisl, W Gebauer, D Reschke, E Ost, R Husmann, 
  8. M Klee, D Reichert, B Rosien, F del Valle, I Zirpel, KP Kohse, F Schunter, HJ Illiger Med Klinik 2002; 97:650-8 A multinational European Study on Secondary Prophylaxis of Invasive Fungal Infektion. ID Working Party of the German Society of Hematology and Oncology. Vortrag 42. ICAAC 2002
  9. Clinical use of trastuzumab (Herceptin): Aspects, effects and perspectives. Jackisch C, W Schoenegg, U Söling, M Stauch, G Krieger, D Reichert, P Klare, H Sülberg San Antonio Breast Cancer Symposium 2003
  10. Breakthrough Invasive Fungal Infection (IFI) during secondary prophylaxis (SP). Detection of Predictor Variables. Results from a European Registry. OA Cornely, U Bethe, A Böhme, D Buchheidt, S Cesaro, M Karthaus, J Maertens, R Martino, D Reichert, S Reuter, K Römer, M Sieniawski, AJ Ullmann Heidelberg, 2003
  11. Secundary prophylaxis of invasive fungal infection across europe. M Sieniawski, A Böhme, M Karthaus, G Maschmeyer, R Martino, D Reichert, D Buchheidt, G Silling, W Krügerl K Öhler, X Schiel, AJ Ullmann, A Gratwohl, A Glasmacher, H Lövenich, G Fätkenheuer, OA Cornely Münster 2003
  12. Multinational register on secondary prophylaxis of Invasive Fungal Infection. ID Working Party of the german society of Hematology and Oncology. DGHO 2003
  13. Detection of Predictor Variables for Breakthrough Invasive Fungal Infection (IFI) during Secondary Prophylaxis (SP).Results from a European Registry. OA Cornely, U Bethe, A Böhme, D Buchheidt, S Cesaro, M Karthaus, J Maertens, R Martino, G Maschmeyer, D Reichert, S Reuter, K Römer, M Sieniawski, AJ Ullmann 43. ICAAC 2003
  14. PEG-Asparaginase in Combination with High-Dose Methotrexate for Consolidation in adult ALL in first remission. A pilot study. A Rosen, HJ Müller, N Gökbuget, W Langer, N Peter, D Reichert, S Schwarz, R Depenbusch, D Hähling, F Hartmann, G Helm, TH Ittel, R Mück, F Rothmann, K Troll, R Arnold, J Boos, D Hoelzer Brit J Cancer 2003
  15. Once-Daily Oral Levofloxacin Monotherapy versus Piperacillin/Tazobactam three Times a Day: A Randomized Controlled Multicenter trial in Patients with Febrile Neutropenia OA Cornely, T Wicke, H Seifert, U Bethe, M Schwonzen, D Reichert, A Ullmann, M Karthaus, K Breuer, B Salzberger, V Diehl, G Fätkenheuer Int J Hem 79(2004)74-78
  16. Once weekly epoetin beta in patients with metastatic breast cancer receiving anthracycline- or taxane-based chemotherapy- an interim report. RC Leonard, M Aapro, S Chan, LY Dirix, J Mayordomo, D Reichert, M Untch 29. ESMO Congress, Wien 2004
  17. Efficacy of Secondary Antifungal Prophylaxis (SP) and Risk Factors for Breakthrough Infection (IFI) after pulmonary IFI in AML Patients. OA Cornely, A Böhme, S Reuter, D.Reichert, G.Maschmeyer, G.Silling, J Maertens, AJ Ullmann, R Martino, M Karthaus, S Wacker, G Wassmer 44. ICAAC 2004
  18. Results from a European Registry: Summary of breakthrough invasive fungal infections during subsequent neutropenia. OA Cornely, U Bethe, A Böhme, D Buchheidt, S Cesaro, M Karthaus, J Maertens, R Martino, G Maschmeyer, D Reichert, S Reuter, K Römer, M Sieniawski, AJ Ullmann
  19. Three-Armed Multicenter Randomized Study on the Empiric Treatment of Neutropenic Fever in a High-Risk Patient Population (PEG Study III). OA Cornely, D Reichert, D Buchheidt, G Maschmeyer, M Wilhelm, X Schiel, B Glass, G Fätkenheuer, H Link, M Helmerking, D Adam, W Hiddemann
  20. Once weekly epoetin beta in patients with metastatic breast cancer receiving anthracycline- or taxane-based chemotherapy- an interim report. M Aapro, RC Leonard, A Barnadas, M Marangolo, M Untch, NA Malamos, JI Mayordomo, D Reichert, B Pedrini, L Ukarma, A Scherhag, HU Burger 29. SABCS, 2006, San Antonio
  21. European Registry on breakthrough invasive fungal infection during secondary prophylaxis: Preliminary results on predictor variables. OA Cornely, U Bethe, A Böhme, S Reuter, D Reichert, D Arenz, J Franz, K Römer, M Sieniawski, G Maschmeyer, AJ Ullmann, R Martino, M Karthaus, D Buchheidt, J Maertens, S Cesaro, W Jendrzejczak, M Schmalzing, , A Haas, G Silling, A Gratwohl
  22. Risk Factors of breakthrough invasive fungal infection (IFI) under secondary prophylaxis (SP) – a Multinational European Study. OA Cornely, U Bethe, M Sieniawski, A Böhme, S Reuter, D Reichert, G Maschmeyer, AJ Ullmann, M Karthaus, D Buchheidt, R Martino, H Einsele, A Haas, W Jendrzejczak, G Silling, L Öhler, X Schiel, H Auner, A Glasmacher, W Krüger, A Grathwohl, M Sandherr 13. Focus on Fungal Infections, Maui, Hawaii
  23. Central European Society for anticancer drug resarch-EWIV (CESAR-EWIV): Phase I- und II-studies. Ch Dittrich, J Beck, D Behringer, C Bokemeyer, M Borner, M deSantis, G Fiebig, G Gastl, D Hossfeld, HJ Illiger, R Morant, K Mross, W Queißer, D Reichert, ME Scheulen, J Schüller, J Von Pawel
  24. Liposomal Amphotericin B as Initial Therapy for Invasive Mold Infection: A Randomized Trial Comparing a High-Loading Dose Regime with Standard Dosing (AmBiLoad Trial) OA Cornely, J Maertens, M Bresnik, R Ebrahimi, AJ Ullmann, E Bouza, CP Heussel, O Lortholary, C Rieger, A Boehme, M Aoun, HA Horst, A Thiebaut, M Ruhnke, D Reichert, N Vianelli, SW Krause, E Olavarria, and R Herbrecht CID 2007:44 (15 May)
  25. CELER: An International Randomized Phase III Trial of the CESAR Group- or: Should Chemotherapy be added to Hormonal Therapy in Advanced Breast Cancer . D.Sirbu, C.Oprean, M.Draganescu, V.Valeanu, D.Reichert, S.Eder, B.Moritz, L.Edler , R.Morant St. Gallen Primary Therapy of Early Breast Cancer , 10th International Conference, 2007
  26. Caspofungin use in daily clinical practice for Treatment of Invasive Aspergillosis - Results of a Prospective Observational Registry J Maertens, G Egerer, WS Shin, D Reichert, M Stek, S Chandwani, M Shivaprakash, C Viscoli for the CAN-DO(IA) study team. Poster No.P1017, 18th ECCMID 2008, Barcelona, Spain
  27. Efficacy of Caspofungin compared to Itraconazole as Secondary Antifungal Prophylaxis: A Multinational Case Registry. J Vehreschild, M Sieniawski, S Reuter, D Reichert, J Maertens, A Böhme, G Silling, G Maschmeyer, A Ullmann, OA Cornely ECCMID 2008, in Planung
  28. Effect of Once Weekly Epoetin Beta on Survival in Patients With Metastatic Breast Cancer Receiving Anthracycline- and/or Taxane-Based Chemotherapy-Results of the BRAVE Study. M Aapro, RC Leonard, A Barnades, M Marangolo, M Untch, N Malamos, J Mayordorno, D Reichert, JL Pedrini, L Ukarma, A Scherhag, and HU Burger J Clin Oncol 26 (2008) 285-289
  29. Risk factors for breakthrough invasive fungal infection during secondary prophylaxis. OA Cornely; A Bohme; D Reichert; S Reuter; G Maschmeyer; J Maertens; D Buchheidt; M Paluszewska; D Arenz; U Bethe; J Effelsberg; H Lovenich; M Sieniawski; A Haas; H Einsele; H Eimermacher; R Martino; G Silling; M Hahn; S Wacker; AJ Ullmann; M Karthaus; on behalf of The Multinational Case Registry of the Infectious Diseases Working Party of the German Society for Hematology and Oncology Journal of Antimicrobial Chemotherapy 2008
  30. Treatment of invasive fungal infections in clinical practice: a multi-centre survey on customary dosing, treatment indications, efficacy and safety of voriconazole. JJ Vehreschild, A Böhme, D Reichert, MG Kiehl, D Arenz, K Pankraz, M Kochanek, AJ Ullmann, OA Cornely Int J Hematol (2008) 87:126-131
  31. Trastuzumab treatment in elderly patients with advanced breast cancer (ABC)-results from a large observational study. C Jackisch, A Hinke, W Schoenegg, U Soeling, M Stauch, T Goehler, W Kuehn, G Krieger, D Reichert 31st Annual San Antonio Breast Cancer Symposium
  32. Caspofungin for treatment of invasive aspergillosis: Results of a pre-planned secondary analysis of the German patients of a prospective observational registry. G Egener, D Reichert, MW Pletz, J Maertens, P Kaskel, M Shivaprakash, C Viscoli Joint Meeting of the German, Austrian and Swiss Societies for Hematology and Oncology, Wien 2008
  33. Results of the non-interventional TARGET study - Efficacy and safety of nilotinib in routine clinical management of CML patients (pts) failing prior therapy. J Dengler, P le Coutre, F stegelmann, M C Müller, A Sauer, U Schwinger, T Ulshöfer, D Reichert, W Schneider-Kappus, S Stern, U Vehling-Kaiser, C Waller, C Losem, M Meincke, O Frank, O G Ottmann.
  34. Noninterventional study HELENA-Advanced (metastatic or locally recurrent, inoperable) HER2-positive breast cancer: First-Line treatment with pertuzumab after adjuvant trastuzumab therapy. M Thill, K Ziegler-Löhr, H Wagner, G Helling-Giese, J Greinemann, O Schmalhofer, D Reichert, SABCS 2014
  35. Panitumumab as first and second line combination therapy of patients with RAS wild-type metastatic colorectal cancer (mCRC): interim results of the first community-based, observational study. H Hebart, HW Tessen, H Linde, R Koukakis, A Rieth, E Hellebrand, D Reichert; DGHO Basel 2015
  36. First interim analysis of OTILIA, a large German non-interventional study evaluating bevacizumab-containing therapy in patients with ovarian cancer. A Mustea, S Mahner, G Oskay-Öscelik, P Wimberger, P Jungberg, D Reichert, H Forstbauer, M Keller, R Richter, M Frank, S Klawitter, C Kiewitz, M Müller, J Sehouli. ESMO 2015 Vienna
  37. A non-comparative, single-arm observational study conductedas a non-interventional study (NIS) to monitor the routine clinical practice of Bevacizumab in combination with platinum-based chemotherapy in patients with unresectable advanced, metastatic or recurrent adenocarcinoma of the lung in Germany. H Wirtz, S Lang, J Mezger, T Gaska, C Lerchenmüller, M Reck, H Held, D Reichert, G Hoeffken. ESMO 2015, Vienna
  38. Efficacy od trastuzumab re-therapy in the clinical routine of HER2-positive breast cancer patients who relapsed after completed anti-HER2 (neo)adjuvant therapy-5th interim analysis of the national non-interventional study (NIS) ML21589. LC Hanker, T Hitschold, A Grafe, F Förster, J Schröder, J Janssen, D Reichert, C Hielscher, S Keitel, T Hesse. SABCS 2015
  39. Identification of patients (pts) at high risk for early death with advanced or metastatic breast cancer (MBC), not receiving salvage treatment after 1th-line (1thL) therapy with trastuzumab (T) - results of a prospective national non-interventional study (NIS) in Germany. C Jackisch, W Schoenegg, D Reichert, M Weislau, J Selbach, HD Hanch, H Tesch, S Keitel, A Hinke. SABCS 2015 
  40. A first community-based, observational study on panitumumab as 1th and 2nd line combination therapy of metastatic colorectal cancer (nCRC) in RAS wild-type patients. H Hebart, HW Tessen, H Linde, R Koukakis, A Rieth, E Hellebrand, D Reichert. DKK 2016
  41. First interim analysis of OTILIA, a large German non-interventional study evaluting front-line bevacizumab-containing therapy in patients with ovarian cancer. A Mustea, G Oskay-Oezcelik, P Wimberger, D Reichert, H Forstbauer, M Keller, M Frank, S Klawitter, C Kiewitz, M Mueller, J Sehouli. #2754 ECC, Vienna, 2015
  42. Preliminary safety and efficacy results from the multicentre OTILIA observational study of bevacizumab-containing therapy in women with newly diagnosed ovarian cancer in Germany. P Wimberger, A Mustea, G Oskay-Oezcelik, W Meinerz, D Reichert, H Forstbauer, M Keller, M Frank, S Klawitter, C Kiewitz, M Mueller, J Sehouli. #0919 ESGO, Nice, 2015
  43. Panitumumab als 1. und 2. Linienkombinationstherapie des metastasierten Kolorektalkarzinoms vom RAS-Wildtyp im Versorgungsalltag. H Hebart, HW Tessen, H Linde, R Koukakis, A Rieth, E Hellebrand, D Reichert. DKK 2016
  44. Patient reported outcomes in elderly bevacizumab-treated primary ovarian cancer patients: OTILIA Study on behalf of the North-Easzern German Society of Gynaecological Oncology. A Mustea, G Oskay-Oezcelik, P Wimberger, D Reichert, H Forstbauer, M Keller, M Frank, S Klawitter, C Kiewitz, M Mueller, J Sehouli. Abstract IGCS-0471, IGCS 2016, ESMO 2016
  45. Treatment of AML patients with Azacitidine in a Routine care Setting in Germany. Data from an unplanned interim subgroup Analysis of the non-interventional Observational Study on Treatment Patterns with VIDAZA. G Prange-Knex, D Reichert, A Lollert, HR Bruch, HW Tessen, P Ferenczy, C Weilimann, C Steudel, U Platzbecker. DGHO 2017 Stuttgart
  46. Bevacizumab (Bev)-based combination therapy across treatment lines in patients (pts) with metastatic colorectal cancer (mCRC)-interim analysis results from a German non-interventional study (KORALLE), E Eggers, J Uhlig, D Reichert, A Wein, H Schulz, A Behringer, D Arnold, DGHO 2017 Stuttgart